Mohammad Jad Moussa

Mohammad Jad Moussa: Original Series on ICIs in aUA and aNUA of the Urinary Tract at SITC2024

Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:

“SITC2024 GUsm: Original Series on ICIs in Advanced Urachal (aUA) and Non-Urachal Adenocarcinomas (aNUA) of the Urinary Tract – Omar Alhalabi, Matt Campbell, MD Anderson Cancer Center.

  • n=22; chemo-exposed (91%), visceral mets (UA: lung ++ peritoneum +/ NUA: lung ++ bone +), 71% single-agent ICI, 29% nivo/ipi
  • Limited ICI efficacy (ORR 14.3%, mPFS 4.9 mo) in aUA (n=14), genetic signatures ~ colorectal adeno (TP53, KRAS, GNAS, SMAD4) 
  • Same pattern in aNUA (smaller cohort, ORR 12.5%, mPFS 2.4 mo), genetically ~ to urothelial ca (TP53, RB1)
  • 2 of 3 responses with nivo/ipi -> role of ICI combination or CTLA-4i?

Larger cohorts needed.”

Mohammad Jad Moussa: Original Series on ICIs in aUA and aNUA of the Urinary Tract at SITC2024

More posts featuring Mohammad Jad Moussa.

cancer Mohammad Jad Moussa OncoDaily Oncology